April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Study Results Suggest Waiting Longer Before Resecting Hepatocellular Adenomas
May 17th 2017Current guidelines recommend waiting 6 months before resecting a large hepatocellular adenoma to prevent a transformation to a malignant tumor; however, a recent study suggests that waiting longer could benefit some patients.
Read More
Nivolumab a Valuable Option in HCC, Lead CheckMate-040 Investigator Says
May 3rd 2017Nivolumab (Opdivo) demonstrated promise as a second-line therapy for patients with hepatocellular carcinoma (HCC), according to results of the CheckMate-040 trial presented at the 2017 International Liver Congress.
Read More
AFP Level Identified as a Potential Biomarker for Survival in HCC
April 24th 2017According to an assessment of a large global dataset reported at the 2017 International Liver Congress, log<sub>10</sub> alpha fetoprotein level in the blood directly corresponded to the years of posttreatment survival in patients with hepatocellular carcinoma.
Read More
SIRT May Be Better-Tolerated Alternative to Sorafenib in Advanced HCC, Study Findings Show
April 24th 2017In patients with hepatocellular carcinoma, liver-targeting treatment with selective internal radiation therapy more effectively controlled liver tumor progression and was better tolerated, but the therapy did not improve rates of overall or progression-free survival over sorafenib.
Read More
Majority of Patients Experience Disease Stabilization With Mipsagargin in Refractory HCC Trial
April 24th 2017Mipsagargin, a first-in-class prodrug, showed promising antitumor activity and enabled patients with advanced sorafenib-refractory hepatocellular carcinoma to achieve disease stabilization.
Read More
Higher Risk of HCC Recurrence Observed Following DAA Therapy for Hepatitis C
April 21st 2017In updated results presented at the 2017 International Liver Congress, Spanish researchers raised a red flag regarding observations of unexpected higher rates of hepatocellular carcinoma recurrence following treatment with direct-acting antivirals for hepatitis C virus infection.
Read More
Researchers Identify Independent Prognostic Factors of HCC Recurrence
April 21st 2017Researchers have identified higher levels of hepatocytes positive for pERK immunostaining and greater microvascular invasion as independent prognostic factors of recurrence in patients treated with sorafenib Nexavar for hepatocellular carcinoma.
Read More
Exploring the Potential for MicroRNA-34a as a Tumor Suppressor in HCC
April 21st 2017Results from a study of microRNA-34a and natural killer cells presented at the 2017 International Liver Congress suggest that microRNA-34a, one of the most documented tumor suppressor microRNAs, could have a role in regulating cytotoxicity and development of the effector NK cells and their target cells.
Read More
Hepatitis C Patients At No Elevated Risk of Developing HCC Following DAA Compared To Interferon
April 20th 2017Patients were at no elevated risk of developing hepatocellular carcinoma after achieving sustained virologic response following treatment with direct-acting antiviral therapy for hepatitis C compared to interferon therapy.
Read More
Welling to Lead New Liver Cancer Program at NYU Langone
February 20th 2017NYU Langone has announced Theodore H. Welling III, MD, will lead a new state-of-the-art liver cancer program at the medical center to advance clinical care and accelerate the translation of lab breakthroughs into superior treatments.
Read More
Progression Type Impacts Survival in HCC, RESORCE Analysis Shows
January 23rd 2017Supporting the concept of post-progression survival and the influence of different patterns of progression, a new analysis showed patients with advanced HCC had a worse survival following progression if they developed new extrahepatic lesions as opposed to other types of progression.
Read More